Explore original, structured summaries for research and education.
Research profile
ACE-031(ACVR2B-Fc)
ACE-031(ACVR2B-Fc) is indexed as a Soluble activin receptor type IIB-Fc fusion protein research entry. Its current evidence category is (ACVR2B-Fc), and published discussion commonly places it within Growth Hormone. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- —
- Chain length
- —
- Type
- Soluble activin receptor type IIB-Fc fusion protein
- Reported half-life
- 12-15 days
Literature map
Research indications
Muscle Growth
- Muscle Hypertrophymost effective
- Muscular Dystrophyeffective
- Muscle Wasting / Cachexiaeffective
Body Composition
- Fat Losseffective
- Bone Densitymoderate
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for ACE-031(ACVR2B-Fc). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of ACE-031(ACVR2B-Fc) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is ACE-031(ACVR2B-Fc) approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- A soluble activin receptor type IIB (ACE-031) increases lean body mass and muscle strength in healthy postmenopausal womenAttie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML · Journal of Clinical Endocrinology & Metabolism · 2013
- A phase 2 trial of ACE-031, a soluble activin receptor type IIB, in boys with Duchenne muscular dystrophyCampbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Bhatt SA, Trachtenberg FL, Kunkel LM, Bhatt RS · Neuromuscular Disorders · 2017
- Pharmacokinetic, pharmacodynamic, and safety results from a first-in-human study of ACE-031, a novel activin receptor type IIB/Fc fusion proteinBhatt RS, Goss A, Wilson DM, Borgstein NG, Sherman ML · Journal of Clinical Pharmacology · 2014
- Myostatin inhibition in health and diseaseLee SJ · Annual Review of Cell and Developmental Biology · 2004